Montreal Breaking - Fifty 1 Labs and UAV Corp to Host Virtual Shareholder Teleconference Featuring Nobel Laureate Dr. James Orbinski

Fifty 1 Labs, Inc. (OTC: FITY), in collaboration with UAV Corp (OTC: UMAV), is set to host a virtual shareholder teleconference on July 28, 2025, at 12:00 PM EST, featuring Nobel Laureate Dr. James Orbinski. The event, to be streamed live on X (formerly Twitter), aims to showcase Fifty 1 Labs’ strategic roadmap for its subsidiary, Fifty 1 AI Labs, including advancements in AI-driven drug repurposing for functional medicine and a significant R&D investment. The company’s commitment to aligning with shareholder interests is evident through personal investments and deferred salaries by management, underscoring a shared vision for growth and global health impact.

Dr. Orbinski, who accepted the 1999 Nobel Peace Prize on behalf of Médecins Sans Frontières, will lend his expertise to the discussion, highlighting the potential of AI in revolutionizing health and wellness solutions. Fifty 1 Labs’ focus on off-patent drug repurposing and adaptive trials positions it uniquely in the biotech and wellness sectors, with plans for a $5–10 million biotech acquisition by 2027. This initiative reflects the company’s ambition to leverage technology for personalized medicine and biodefense applications, building on the success of its GeneScape platform developed by Genetic Networks LLC, a wholly-owned subsidiary.

The teleconference represents a pivotal moment for Fifty 1 Labs and UAV Corp, as they seek to engage shareholders and the broader public in their vision for the future of health and wellness. By integrating AI with biotech innovations, the companies aim to address some of the most pressing challenges in global health, offering scalable solutions that could transform patient care and drug discovery processes. For more information on the event, visit https://ibn.fm/vdzmf.